论文信息 - The Image of Pharma

The Image of Pharma

aminocaproic These findings indicate that in addition to the previously reported acute renal and vascular safety concerns, aprotinin use is associated with an increased risk of long-term mortality following CABG surgery. Use of aprotinin among patients undergoing CABG surgery does not appear prudent because safer and less expensive alternatives (i.e., aminocaproic acid and tranexamic acid) are available (Mangano, 2007).

Ajai R. Singh | Shakuntala A. Singh

[1] A. Hoeft,et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. , 2007, JAMA.

[2] Ajai R. Singh,et al. Academia, Journal Publishing and the Bio-Medical Industry , 2007, Mens sana monographs.

[3] J. Lenzer. Researcher received undisclosed payments of $300 000 from Pfizer , 2006, BMJ : British Medical Journal.

[4] I. C. Tudor,et al. The risk associated with aprotinin in cardiac surgery. , 2006, The New England journal of medicine.

[5] Jordan J. Cohen,et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. , 2006, JAMA.

[6] Ajai R. Singh,et al. Medicine As a Corporate Enterprise, Patient Welfare Centered Profession, or Patient Welfare Centered Professional Enterprise? , 2005, Mens sana monographs.

[7] Ajai R. Singh,et al. Public Welfare Agenda or Corporate Research Agenda? , 2005, Mens sana monographs.

[8] J. R. Scotti,et al. Available From , 1973 .